Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. - sprookjes - yvandenbroek - TriplyDB

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

http://www.wikidata.org/entity/Q34003925

about

Bisphosphonates for preventing and treating osteoporosis in men Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy Intravenous zoledronate for postmenopausal osteoporosis European guidance for the diagnosis and management of osteoporosis in postmenopausal women Bisphosphonates: mechanism of action and role in clinical practice Once-yearly zoledronic acid in hip fracture prevention Intravenous zoledronate for osteoporosis: less might be more Surgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature review The Relationship between Metabolic Syndrome and Osteoporosis: A Review Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis Prevention and treatment of bone fragility in cancer patient Clodronate: new directions of use Emerging Therapies for Osteoporosis Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Calcium intake and bone mineral density: systematic review and meta-analysis Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients The evolution of selective estrogen receptor modulators in osteoporosis therapy The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice Osteoporosis Treatment: When to Discontinue and When to Re-start Treatment of primary osteoporosis in men Screening, diagnosis and treatment of osteoporosis: a brief review Bisphosphonate drug holiday: choosing appropriate candidates Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives Denosumab for the treatment of osteoporosis An overview on the treatment of postmenopausal osteoporosis Denosumab: mechanism of action and clinical outcomes Do bisphosphonates cause femoral insufficiency fractures?A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma Bone anabolics in osteoporosis: Actuality and perspectives Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil Increasing options for the treatment of osteoporosis Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials Effectiveness of a minimal resource fracture liaison service Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83 Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.

P2860

Q24197612-83411F76-340E-4B2F-B348-E6A4ADEE6260 Q24198280-A74579D1-DEBF-430C-B88E-1C30B659788F Q24239823-126DD01E-9837-479D-BF13-DF455365A810 Q24612411-D8B9339E-29BC-432D-976F-693DFCDF11D7 Q24644708-62A434A0-7D19-4F3D-A1F5-931BE8A98180 Q24657667-98737373-9B29-4622-94E8-A1E4DEE2E590 Q26738958-A53FCE29-D693-4F45-98A6-1E66A4DDAD0D Q26744057-8D548379-10E8-4B8E-A537-0F3D42A75F68 Q26747451-9C7256DB-5121-4ECB-B8A7-2C1FF20935D5 Q26749442-AAAFFEF6-D47F-4DD4-9FC4-F064939FFEB4 Q26752588-C9981FA6-A077-4BBC-B698-70174FAB9609 Q26775765-AC4AC76C-34CB-424D-B233-9B387E97F27D Q26775773-45676B9A-65B5-4D97-9B40-D18227243F83 Q26782109-2609FE09-719D-4680-9F93-18FB9BA34E32 Q26782621-4DBA104C-0288-4CD1-B2DD-EA9AD7EAAFEE Q26784337-C0B5B4B4-281C-4414-B407-EADE31601DB9 Q26824762-99567998-3908-4002-A9D8-9315B696E7E9 Q26827973-09B168D8-EAE6-4E47-B4AD-FA755FB8F990 Q26830744-6899E872-B369-439E-8F52-10390C61AD2C Q26858980-CDB55936-DFE3-4392-AFC7-15D7807E4996 Q26991748-DD8C8AA9-FD4F-4F5B-B87E-BD4BF6D4667A Q26996726-B69F7784-0961-4CB8-B2F4-171B695FEB84 Q27004682-596B7845-C2AC-4326-A27C-6F7470AA5D4E Q27005978-5A856981-30A7-467A-991E-E46C1938A7C4 Q27009275-54006396-5501-4E44-A603-8F47D76AF972 Q27013070-2211D585-9D89-4897-9891-BC1E6D945312 Q27015899-0DB7F03F-BB87-458F-AAD1-1E56BC1E62E7 Q27021396-DE0348E9-D61B-4EAC-B419-F9ED42ECCFBE Q27302911-8DC41B7B-E365-47B5-947F-D1C0490FC1B2 Q27691122-FDB6B7B1-3FBE-46AA-BF0A-785B99FB1B7C Q28079133-C19C5702-7C0F-44B1-8DC2-1D8EDF7A0F65 Q28080673-FE199488-7925-400F-8919-06FD267CA9F3 Q28254516-6C4388A2-24D1-4A06-9D88-F0D257913830 Q28269986-3D1413D7-E218-426E-B5D8-A8ECB33BA22D Q28391373-9746EDA3-0B4D-4F1D-9BBE-C9DF25409F9C Q28540022-B65ACB01-3104-40A9-BB73-100254C6586A Q28540086-F6655216-4D01-48A7-AE33-F6FAEFD976BD Q28552191-EF0AC98B-789B-4F8A-B846-9FAE35006225 Q28569888-E6F2CD9D-A712-4A17-9BC8-4DADA22F6CAC Q30235173-844B0343-A049-4A75-88FF-D3D9DEEF9BB0

P2860

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

http://www.wikidata.org/entity/Q34003925

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@ast

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@en

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@nl

type

label

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@ast

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@en

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@nl

prefLabel

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@ast

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@en

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@nl

P1433

Q34003925-D69EF057-9835-4E3D-8A37-406CF0FB8DD1

P1476

Q34003925-476FE804-E5A5-485F-9123-09A2B4090730

P2093

Q34003925-05F520DE-4851-4A39-B5F9-D2EEB0432526

Q34003925-1A502AAE-9C6A-49F6-A512-1CD96654B2B8

Q34003925-5BF9D8B9-772B-4DC1-B818-79504D965E6F

Q34003925-714CFC52-5C62-4556-8068-59E22EEB2404

Q34003925-8FA49E13-B5D2-4CA7-BD81-8010BF2732B1

Q34003925-94007DDF-37C4-4A18-A9DA-559D14C25164

Q34003925-9CB1ED42-091C-42C5-93E5-980D8A975818

Q34003925-A21AE722-AC59-458D-A589-80777E207055

Q34003925-A2AE76FC-81C1-4125-A445-0892C056D2E8

Q34003925-A58796EF-E84F-498E-8A57-838FD2D0F5CD

P304

Q34003925-BA3662A3-F18A-43EC-993B-0303B0335BB1

P31

Q34003925-A7593E59-B810-4A1A-91D7-FEB6661F9083

P356

Q34003925-6B1925BC-49AA-41E3-81AE-83F09FBD7B1F

P407

Q34003925-ECBA4841-78DA-4F62-AB28-006F0754BFAB

P433

Q34003925-FD48ED4B-E424-4832-9DDD-EBD885469413

P478

Q34003925-6A46BEE5-E824-4D13-BA2A-333E12494B09

P50

Q34003925-22C62FF3-E8BB-4ADF-982B-16A9FBE5E24D

Q34003925-870641F9-FD54-4E16-ABFC-144DA1B4C413

P577

Q34003925-9DC26DEB-5E3D-4797-B0EF-B3462321ED9A

P698

Q34003925-61069E90-A33A-4F2D-B786-4BDAF07E8BE5

Q34003925-7339407b-0494-41a1-a0e2-a89e1da0c067

P921

Q34003925-B19C4F90-4DCA-4ABF-8E93-8B26D6D44CFF

P356

P1433

The New England Journal of Medicine

P1476

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

@en

P2093

Carlos Mautalen

http://www.w3.org/2001/XMLSchema#string

Deborah Sellmeyer

http://www.w3.org/2001/XMLSchema#string

Dennis M Black

http://www.w3.org/2001/XMLSchema#string

Erik Fink Eriksen

http://www.w3.org/2001/XMLSchema#string

Felicia Cosman

http://www.w3.org/2001/XMLSchema#string

HORIZON Pivotal Fracture Trial

http://www.w3.org/2001/XMLSchema#string

Huilin Hu

http://www.w3.org/2001/XMLSchema#string

Joel Krasnow

http://www.w3.org/2001/XMLSchema#string

John Caminis

http://www.w3.org/2001/XMLSchema#string

Karen Tong

http://www.w3.org/2001/XMLSchema#string

P304

1809-1822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA067312

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

356

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17476007

http://www.w3.org/2001/XMLSchema#string

P921